logo
Twitter
Discord
Email
logo
Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc.

NASDAQ•TVGN
CEO: Dr. Ryan H. Saadi M.D., M.P.H, M.P.H.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2022-01-05
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Contact Information
15 Independence Boulevard, Suite #410, Warren, NJ, 07059, United States
877-838-6436
tevogen.com
Market Cap
$69.52M
P/E (TTM)
-2.2
37
Dividend Yield
--
52W High
$1.92
52W Low
$0.30
52W Range
3%
Rank49Top 66.7%
3.2
F-Score
Modified Piotroski Analysis
Based on 4-year fundamentals
Weak • 3.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2022-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.03-13.54%
4-Quarter Trend

FCF

-$3.65M-4.08%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Quarterly Operating Expense Reduction Total operating expenses for three months ended Sep 30, 2025 were $5.73M, down from $6.09M in 2024; Net loss narrowed to $(5.73M).
Liquidity Runway Secured Cash balance $1.04M; management expects funding plus $3.9M Sales Agreement proceeds covers next 12 months operations.
Financing Activities Remain Stable Net cash provided by financing activities totaled $9.90M for nine months 2025, similar to $10.23M provided in the prior year period.
R&D Spending Decreased YTD Nine months R&D expenses dropped to $9.01M in 2025 from $28.20M in 2024, primarily due to lower stock-based compensation.

Risk Factors

Assumed Notes Payable Default Notes payable of $1.651M assumed during Merger are in default as of September 30, 2025; no immediate penalty provisions apply.
Nasdaq Listing Compliance Risk Received Nasdaq notification for failing minimum $1.00 bid price requirement; 180 days to regain compliance by March 23, 2026.
Stockholders' Deficit Widened Total stockholders' deficit increased to $(7.82M) as of September 30, 2025, compared to $(6.67M) at year-end 2024.
High Cash Burn Rate Cash used in operating activities totaled $(10.15M) for nine months 2025, higher than $(8.98M) used in the prior year period.

Outlook

Substantial Future Funding Required Requires substantial additional capital to pursue objectives; failure to secure funding forces delay, limit, or termination of development programs.
Advance Key Product Candidates Expect R&D expenses to increase supporting planned clinical trials for TVGN 489 and expanding Tevogen.AI capabilities.
Commercialization Expense Anticipated If approval is obtained for TVGN 489, expect significantly increased expenses related to manufacturing, sales, marketing, and distribution efforts.

Peer Comparison

Revenue (TTM)

C4 Therapeutics, Inc.CCCC
$30.11M
-10.6%
Spero Therapeutics, Inc.SPRO
$30.08M
-68.5%
Nuvectis Pharma, Inc.NVCT
$26.80M
-753.4%

Gross Margin (Latest Quarter)

C4 Therapeutics, Inc.CCCC
100.0%
+13.4pp
Spero Therapeutics, Inc.SPRO
100.0%
+0.0pp
PepGen Inc.PEPG
0.0%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
CYBN$413.02M-2.5-51.8%15.9%
PEPG$374.68M-1.9-84.1%9.2%
GLSI$352.88M-17.8-1042.8%0.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 25, 2026
|
EPS:-
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 14, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.03-13.5%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 14, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.03-22.3%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 14, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.07-181.4%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Apr 2, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.09-23300.0%
    N/A

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 19, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.03+40.5%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 14, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.04-75.4%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 28, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $0.08-130.8%
    N/A

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Apr 29, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.00-101.1%
    N/A